哮喘和慢性阻塞性肺疾病(COPD)是最常见的呼吸道疾病之一,全球分别有3 亿和2.1 亿患者。肺部吸入给药是治疗和管理哮喘、COPD 等呼吸道疾病的首选给药方式,而患者的依从性与该类制剂的疗效优劣有密切关系。综述现在已经上市的肺部吸入给药治疗哮喘和慢性阻塞性肺疾病的主要剂型和药品,以及雾化吸入剂、定量吸入剂和干粉吸入剂对患者依从性的影响,并认为提高患者依从性需要反复提供给患者个性化用药和正确使用给药装置的指导。

Asthma and chronic obstructive pulmonary disease (COPD) are common respiratory diseases. Globally, 300 million people suffer from asthma and 210 million people from COPD respectively. Pulmonary drug delivery is the preferred administration mode for the treatment and management of pulmonary diseases, such as asthma and COPD, and adherence has closely relationship with the efficacy of this inhaler therapy. The main inhalers and inhaler medicines of pulmonary drug delivery available in the marketplace, and the impact of nebulizers, metered-dose inhalers, and dry powder inhalers on the adherence are reviewed. Promoting adherence involves a provision of guidance for personalized administration and right use of pulmonary drug delivery system are concluded.